Τετάρτη 1 Νοεμβρίου 2017

Targeting Angiogenesis in Bladder Cancer [News in Brief]

Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy.



http://ift.tt/2iTuGGj

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου